Balanced activation of striatal output pathways by faster off-rate PDE10A inhibitors elicits not only antipsychotic-like effects but also procognitive effects in rodents.
Faster off-rate competitive enzyme inhibitors are generally more sensitive than slower off-rate ones to binding inhibition by enzyme substrates. We previously reported that cAMP concentration in dopamine D1 receptor-expressing medium spiny neurons (D1-MSNs) may be higher than that in D2-MSNs. Consequently, compared with slower off-rate phosphodiesterase 10A (PDE10A) inhibitors, faster off-rate ones comparably activated D2-MSNs, but partially activated D1-MSNs. We further investigated the pharmacological profiles of PDE10A inhibitors with different off-rates. PDE10A inhibitors with slower (T-609) and faster (T-773) off-rates were used. D1- and D2-MSNs activation was assessed by substance P and enkephalin mRNA induction, respectively, in rodents. Antipsychotic-like effects were evaluated by MK-801- and methamphetamine-induced hyperactivity and prepulse inhibition in rodents. Cognition was assessed by novel object recognition task and radial arm maze in rats. Prefrontal cortex (PFC) activation was evaluated by c-Fos immunohistochemistry in rats. Gene translations in D1- and D2-MSNs were evaluated by translating ribosome affinity purification and RNA sequencing in mice. Compared with T-609, T-773 comparably activated D2-MSNs but partially activated D1-MSNs. Haloperidol (a D2 antagonist) and T-773, but not T-609, produced antipsychotic-like effects in all paradigms. T-773, but not T-609 or haloperidol, activated PFC and improved cognition. Overall gene translation patterns in D2-MSNs by all drugs, and those in D1-MSNs by T-773 and T-609 were qualitatively similar. Differential pharmacological profiles among those drugs could be attributable to activation balance of D1- and D2-MSNs. The "balanced activation" of MSNs by faster off-rate PDE10A inhibitors may be favorable to treat schizophrenia.